In the treatment of asthma, which medication should be added if a SABA fails to improve symptoms?

When a short-acting beta-agonist (SABA) fails to adequately relieve asthma symptoms, adding a long-acting beta-agonist (LABA) is an appropriate step in management. LABAs work by providing prolonged bronchodilation, which is essential for maintaining control over asthma symptoms, especially when quick relief is insufficient. They have a longer duration of action compared to SABAs, making them suitable for individuals whose asthma requires more sustained control.

The use of a LABA in conjunction with inhaled corticosteroids is particularly effective, as it addresses both quick relief and long-term management of asthma. By adding a LABA, patients may experience improved lung function and a decrease in the frequency of asthma attacks. It is important to note that LABAs should not be used as monotherapy but rather in combination with other necessary medications to manage asthma effectively.

Other options, although they can be used as adjunctive therapies depending on the specific circumstances, do not provide the same level of symptomatic relief as a LABA will in situations where a SABA has failed. For example, ipratropium bromide and inhaled anticholinergics can also assist in bronchodilation but might not be the first-line choice after a SABA. Ant